Echinocandin antifungal drugs

Lancet

Volumn 362, Issue 9390, 2003, Pages 1142-1151

  Denning, David W ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CILOFUNGIN; CYCLOSPORIN A; DEXAMETHASONE; DIAZEPAM; ECHINOCANDIN B DERIVATIVE; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; GLUCAN SYNTHASE; HMR 3270; ITRACONAZOLE; METHOTREXATE; MICAFUNGIN; NELFINAVIR; NEVIRAPINE; PHENYTOIN; RIFAMPICIN; SALICYLIC ACID; TACROLIMUS; UNCLASSIFIED DRUG; WARFARIN;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; FEVER; FUNGAL MENINGITIS; FUSARIUM; GENE DELETION; HEADACHE; HEMOLYSIS; HISTAMINE RELEASE; HUMAN; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER NECROSIS; LIVER TOXICITY; MAMMAL CELL; NONHUMAN; PHLEBITIS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; ZYGOMYCETES;

EID: 0141863188     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14472-8     Document Type: Review

References (126)

1. Groll A.H., Shah P.M., Mentzel C., et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 33:1996;23-32.
2. Vogeser M., Haas A., Aust D., Ruckdeschel G. Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis. 16:1997;1-6.
3. Ribaud P., Chastang C., Latge J.P., et al. Outcome and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 28:1999;322-330.
4. Denning D.W. Invasive aspergillosis. Clin Infect Dis. 26:1998;781-805.
5. Moore R.D., Chaisson R.E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 124:1996;633-642.
6. Grant A.D., Djomand G., De Cock K.M. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS. 11:(suppl B):1997;S43-S54.
7. Supparatpinyo K., Khamwan C., Baosoung V., Nelson K.E., Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet. 344:1994;110-113.
8. Moore C.B., Sayers N., Mosquero J., Slaven J., Denning D.W. Antifungal drug resistance in Aspergillus. J Infect. 41:2000;203-220.
9. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2:2002;73-85.
10. Nyfeler R., Keller S.W. Metabolites of microorganisms, 143: echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var echinulatus - isolation and structural components. Helv Chim Acta. 57:1974;2459-2477.
11. Masurekar P.S., Fountoulakis J.M., Hallada T.C., Sosa M.S., Kaplan L. Pneumocandins from Zalerion arboricola, II: modification of product spectrum by mutation and medium manipulation. J Antibiot (Tokyo). 45:1992;1867-1874.
12. Iwamoto T., Fujie A., Sakamoto K., et al. WF11899A, B and C, novel antifungal lipopeptides, I: taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 47:1994;1084-1091.
13. Current W.L., Tang J., Boylan C., et al. Glucan biosynthesis as a target for antifungals: the echinocandin class of antifungal drugs. Dixon F.K., Copping L.G., Holloman D.W. The discovery and mode of action of antifungal drugs. 1995;143 Bios Scientific, Oxford.
14. Kurtz M.B., Rex J.H. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem. 56:2001;423-475.
15. Cabello M.A., Platas G., Collado J., et al. Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms. Int Microbiol. 4:2001;93-102.
16. Ohyama T., Kurihara Y., Ono Y., et al. Aborcandins A, B, C, D, E and F, novel 1,3-beta-glucan synthase inhibitors: production and biological activity. J Antibiot. 53:2000;1108-1116.
17. Pelaez F., Cabello A., Platas G., et al. The discovery of enfumafungin, a novel antifungal compound produced by endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol. 23:2000;333-343.
18. Douglas C. Fungal beta (1,3)-D-glucan synthesis. Med Mycol. 39:(suppl 1):2001;55-66.
19. Klis F.M., de Groot P., Hellingwerf K. Molecular organization of the cell wall of Candida albicans. Med Mycol. 39:(suppl 1):2001;1-8.
20. Bernard M., Latge J.P. Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol. 39:(suppl 1):2001;9-17.
21. Parent S.A., Nielsen J.B., Morin N., et al. Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. J Gen Microbiol. 139:1993;2973-2984.
22. Douglas C.M., Foor F., Marrinan J.A., et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc Natl Acad Sci USA. 91:1994;12907-12911.
23. Douglas C.M., D'Ippolito J.A., Shei G.J., et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 41:1997;2471-2479.
24. Beauvais A., Bruneau J.M., Mol P.C., Buitrago M.J., Legrand R., Latge J.P. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol. 183:2001;2273-2279.
25. Kottom T.J., Limpert A.H. Cell wall assembly by Pneumocystis carinii. J Biol Chem. 275:2000;40628-40634.
26. Mazur P., Morin N., Baginsky W., et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol. 15:1995;5671-5681.
27. Popolo L., Gualtieri T., Ragni E. The yeast cell-wall salvage pathway. Med Mycol. 39:(suppl 1):2001;111-121.
28. Osherov N., May G.S., Albert N.D., Kontoyiannis D.P. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 46:2002;2462-2469.
29. Franzot S.P., Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother. 41:1997;331-336.
30. Del Poeta M., Cruz M.C., Cardenas M.E., Perfect J.R., Heitman J. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 44:2000;739-746.
31. Marchetti O., Moreillon P., Glauser M.P., Bille J., Sanglard D. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother. 44:2000;2373-2381.
32. Lucas R, De Sante K, Hatcher B, et al. LY303366 single dose pharmacokinetics and safety in healthy volunteers. Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 15-18, 1996; New Orleans, USA: abstr F-50.
33. Caspofungin acetate. FDA advisory committee meeting background. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf (accessed Sept 12, 2002).
34. Stone J.A., Holland S.D., Wickersham P.J., et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 46:2002;739-745.
35. Rajman I, Ni L, DeSante K, et al. LY303366 single intravenous dose pharmacokinetics and safety in health subjects. Program and abstracts of the 36th. Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 15-18, 1996; New Orleans, USA: abstr F-74.
36. Krause D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr A-1390.
37. Krause D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects with renal impairment. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr A-1391.
38. Krause D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: Pharmacokinetics in subjects with severe hepatic impairment. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30; 2002; San Diego, USA: abstr A-1392.
39. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr A-1836.
40. Townsend R, Hebert M, Dessimoz M, Wisemandle W, Bekersky H. Pharmacokinetics of micafungin, an echinocandin antifungal, in patients with moderate hepatic dysfunction. Proceedings of the American College of Clinical Pharmacology 31st Annual Meeting; Sept 21-23, 2002; San Francisco, USA: abstr 16.
41. Townsend R, Hebert M, Wisemandle W, Bekersky H. Concomitant pharmacokinetics of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers. Proceedings of the American College of Clinical Pharmacology 31st Annual Meeting; Sept 21-23, 2002; San Francisco, USA: abstr 18.
42. Townsend R, Hebert M, Dessimoz M, Wisemandle W, Bekersky H. Pharmacokinetics of micafungin, an echinocandin antifungal, in patients with severe renal dysfunction. Proceedings of the American College of Clinical Pharmacology 31st Annual Meeting; Sept 21-23, 2002; San Francisco, USA: abstr 17.
43. Holland S, Stone J, Li S, et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, USA: abstr A-14.
44. Shepherd B, Thye D, White RJ, Weston IE, Henkel T. Anidulafungin: a Phase 1 study to identify the maximum tolerated dose in healthy volunteers. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, USA: abstr A-36.
45. Heimenz J, Cagnoni J, Simpson D, Devine S, Chao N. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 26-29, 1999; San Francisco, USA: 576 (abstr 1648).
46. Sirohi, B, Powles R, Chopra R, Russel N, Prentice HG. Assessment of maximum tolerated dose (MTD) of FK463 in cancer patients undergoing haematopoetic stem cell transplantation. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, USA: abstr J-676.
47. Schwartz C, Seibel N, Arriet A, et al. A phase 1 study to determine the safety and pharmacokinetics of FK463 (echinocandin) in febrile neutropenic pediatric patients. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 16-20, 2000; Toronto, Canada: abstr 18.
48. Holland S, Stone J, Li S, et al. Drug interactions between caspofungin and tacrolimus. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, USA: abstr A-13.
49. Thye D, White RJ. Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, USA: abstr A-35.
50. Van der Horst C.M., Saag M.S., Cloud G.A., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 337:1997;15-21.
51. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics of caspofungin in paediatric patients. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr M-896.
52. Pfaller M.A., Jones R.N., Doern G.V., et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis. 35:1999;19-25.
53. Barchiesi F., Schimizzi A.M., Fothergill A.W., Scalise G., Rinaldi M.G. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis. 18:1999;302-304.
54. Mikamo H., Sato Y., Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother. 46:2000;485-487.
55. Tawara S., Ikeda F., Maki K., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 44:2000;57-62.
56. Moore C.B., Oakley K.L., Denning D.W. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect. 7:2001;11-16.
57. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida species. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA; abstr M-230.
58. Cuenca-Estrella M., Mellado E., Diaz-Guerra T.M., Monzon A., Rodriguez-Tudela J.L. Susceptibility of fluconazole-resistant clinical isolates of Candida spp to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother. 46:2000;475-477.
59. Green L.J., Marder P., Mann L.L., Chio L.C., Current W.L. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrob Agents Chemother. 43:1999;830-835.
60. Zhanel G. Zelenitsky N, Laing N, Balko T, Karlowsky J, Hoban D. Correlation between LY303366 area under the concentration curve (AUC) and regrowth of fluconazole-sensitive (FLU-S) and fluconazole-resistant (FLU-R) Candida albicans, using an in vitro pharmacodynamic model. Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 24-27, 1998; San Diego, USA: 454 (abstr J-14).
61. Geiss HK, Dilger S. The post-antifungal effect (PAFE) of caspofungin. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr A-495.
62. Graybill J.R., Najvar L.K., Luther M.F., Fothergill A.W. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother. 41:1997;1775-1777.
63. Abruzzo G.K., Flattery A.M., Gill C.J., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 41:1997;2333-2338.
64. Petraitiene R., Petraitis V., Groll A.H., et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother. 43:1999;2148-2155.
65. Ikeda F., Wakai Y., Matsumoto S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother. 44:2000;614-618.
66. Maesaki S., Hossain M.A., Miyazaki Y., Tomono K., Tashiro T., Kohno S. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother. 44:2000;1728-1730.
67. Abruzzo G.K., Gill C.J., Flattery A.M., et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother. 44:2000;2310-2318.
68. Petraitis V., Petraitiene R., Groll A.H., et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 45:2001;471-479.
69. Petraitis V., Petraitiene R., Groll A.H., et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 46:2002;1857-1869.
70. Graybill J.R., Bocanegra R., Luther M., Fothergill A., Rinaldi M.J. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother. 41:1997;1937-1939.
71. Ju J.Y., Polhamus C., Marr K.A., Holland S.M., Bennett J.E. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice. Antimicrob Agents Chemother. 46:2002;1240-1245.
72. Warn PA, Sharp A, Morrissey G, Denning DW. The in vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused Candida tropicalis. Programs and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr M-187.
73. Kuhn D.M., George T., Chandra J., Mukherjee P.K., Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 46:2002;1773-1780.
74. Bachmann SP, Ramage G, Fothergill A, et al. Combinations of antifungal agents against Candida albicans biofilms in vitro. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: 415 (abstr M-1813).
75. Bartizal K., Gill C.J., Abruzzo G.K., et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 41:1997;2326-2332.
76. Oakley K.L., Moore C.B., Denning D.W. In vitro activity of the echinocandin antifungal agent LY303,366 and comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 42:1998;2726-2730.
77. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:1998;2950-2956.
78. Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 46:2002;245-247.
79. Chiller T., Farrokhshad K., Brummer E., Stevens D.A. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob Agents Chemother. 44:2000;3302-3305.
80. Bowman J.C., Hicks P.S., Kurtz M.B., et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 46:2002;3001-3012.
81. Kurtz M.B., Heath I.B., Marrinan J., Dreikorn S., Onishi J., Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 38:1994;1480-1489.
82. Chiou C.C., Mavrogiorgos N., Tillem E., Hector R., Walsh T.J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother. 45:2001;3310-3321.
83. Verweij P.E., Oakley K.L., Morrissey J., Morrissey G., Denning D.W. Efficacy of LY303366 against amphotericin B "susceptible" and "resistant" A fumigatus infection in a murine model of invasive aspergillosis. Antimicrob Agents Chemother. 42:1998;873-878.
84. Warn P.A., Morrissey G., Morrissey J., Denning D.W. Activity of FK463 against an itraconazole resistant strain of Aspergillus fumigatus and amphotericin B resistant Aspergillus terreus. J Antimicrob Chemother. 51:2003;913-919.
85. Matsumoto S., Wakai Y., Nakai T., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother. 44:2000;619-621.
86. Roberts J., Schock K., Marino S., Andriole V.T. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 44:2000;3381-3388.
87. Groll A.H., Mickiene D., Petraitiene R., et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother. 45:2001;2845-2855.
88. Bowman J.C., Abruzzo G.K., Anderson J.W., et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother. 45:2001;3474-3481.
89. Kirkpatrick W.R., Perea S., Coco B.J., Patterson T.F. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 46:2002;2564-2568.
90. Petraitiene R., Petraitis V., Groll A.H., et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother. 46:2002;12-23.
91. Schmatz D.M., Powles M., McFadden D.C., Pittarelli L.A., Liberator P.A., Anderson J.W. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J Protozool. 38:1991;151S-153S.
92. Powles M.A., Liberator P., Anderson J., et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother. 42:1998;1985-1989.
93. Ito M., Nozu R., Kuramochi T., et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother. 44:2000;2259-2262.
94. Gonzalez G.M., Tijerina R., Najvar L.K., et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother. 45:2001;1854-1859.
95. Kohler S., Wheat L.J., Connolly P., et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother. 44:2000;1850-1854.
96. Roling E.E., Klepser M.E., Wasson A., Lewis R.E., Ernst E.J., Pfaller M.A. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 43:2002;13-17.
97. Perea S., Gonzalez G., Fothergill A.W., Kirkpatrick W.R., Rinaldi M.G., Patterson T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 46:2002;3039-3041.
98. Tamada S, Nakajima M, Yoshida K, et al. Pathological findings in a murine pulmonary aspergillosis model: Treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17-20, 2000; Toronto, Canada: 387 (abstr 1685).
99. Peter J, O'Shaughnessy EM, Walsh TJ. In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr M-856.
100. Petraitiene R, Petraitis V, Sarafandi A et al. Synergistic activity between ravuconazole and the echinocandin micafungin in treatment of experimental pulmonary aspergillosis. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; Sept 27-30, 2002; San Diego, USA: 385 (abstr M-857).
101. Maesaki S, Kohno S, Iwakawa J, et al. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17-20, 2000; Toronto, Canada: 388 (abstr 1686).
102. Kontoyiannis DP, Lewis RE, May GS, Albert ND, Raad II. Sequential exposure of A fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity of this combination. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: abstr M-851.
103. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 33:2001;1529-1535.
104. Arathoon E.G., Gotuzzo E., Noriega L.M., Berman R.S., DiNubile M.J., Sable C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 46:2002;451-457.
105. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 113:2002;294-299.
106. Pettengell K, Mynhardt J, Kluyts T, Simjee A, Baraldi E. A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 16-20, 2000; Toronto, Canada: 371 (abstr 1104).
107. Brown GL, White RJ, Turik M. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 16-20; Toronto, Canada: p 371 (abstr 1106).
108. Press release, 7th October 2002. Versicor announces completion of pivotal phase III study of anidulafungin for oesophageal candidiasis. http://www.versicor.com (accessed Jan 10, 2003).
109. Mora-Duarte, Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 347:2002;2020-2029.
110. Krause D, Goldstein B, Wible M, Kilfoil G, Henkel T. A phase 2 dose-ranging study of the safety and efficacy of anidulafungin in invasive candidiasis (abstract). Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13, 2003; Glasgow, UK: 73 (abstr 403).
111. Maertens J, Raad I, Petrikkos G, et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, USA: 388 (abstr M-686).
112. Ratanatharathorn V, Flynn P, van Burik JA, McSweeney P, Niederwieser D, Kontoyiannis D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients; Proceedings of the 44th Annual American Society of Hematology meeting; Dec 6-10, 2002, Philadelphia, PA, USA: abstr 722.
113. Ullmann AJ, Van Burik JA, McSweeney P et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases; 2003 May 10-13; Glasgow, UK: abstr 722.
114. Kohno S, Masaoka T, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycosis in Japan. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, USA: p 384 (abstr J-834).
115. Van Burik J, Ratanatharathorn V, Lipton J, Miller C, Bunin N, Walsh TJ. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing haematopoetic stem cell transplant. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002, San Diego, USA: 401 (abstr M-1238).
116. Ally R., Schurmann D., Kreisel W., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 33:2001;1447-1454.
117. Kartsonis N., DiNubile M.J., Bartizal K., Hicks P.S., Ryan D., Sable C.A. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr. 31:2002;183-187.
118. Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis. 16:1997;337-345.
119. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 331:1994;1325-1330.
120. Denning D.W., Lee J.Y., Hostetler J.S., et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 97:1994;135-144.
121. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 34:2002;563-571.
122. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 347:2002;408-415.
123. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 96:2000;2055-2061.
124. Steinbach W.J., Stevens D.A., Denning D.W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2002. Clin Infect Dis. 37:(suppl 3):2003;S188-S224.
125. Aliff T.B., Maslak P.G., Jurcic J.G., et al. Refractory Aspergillus pneumonia in patients with acute leukemia. Cancer. 97:2003;1025-1032.
126. Rubin M.A., Carroll K.C., Cahill B.C. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis. 34:2002;1160-1161.